Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
在加速推進的迷幻療法和藥物研發擴張中，生物製藥公司Cybin報告損失7800萬美元。
Cybin Inc. (AMEX:CYBN) (CBOE: CYBN), a clinical-stage biopharmaceutical company focused on developing next-generation psychedelic treatments for mental health disorders, announced Wednesday its financial results for the fiscal quarter and year ending March 31, 2024, alongside significant strides in psychedelic therapy development. Cybin reported a net loss of C$78 million ($57 million) for FY 2024, a noticeable increase from C$47 million the previous year.
Cybin Inc.（美國證券交易所股票代碼：CYBN）（芝加哥期權交易所：CYBN）是一家專注於開發下一代精神健康障礙迷幻療法的臨床階段生物製藥公司，週三公佈了截至2024年3月31日的財季和年度的財務業績，同時迷幻療法開發取得了重大進展。Cybin報告稱，2024財年的淨虧損爲7800萬加元（合5700萬美元），較去年的4700萬加元明顯增加。
Fiscal Year 2024 Financial Highlights
2024 財年財務摘要
No profits or revenues reported.
Net loss was C$78 million.
Cash totaled C$209 million as of March 31, 2024.
Closed oversubscribed private placement of $150 million led by a syndicate of leading biopharmaceutical institutional investors.
未報告任何利潤或收入。
淨虧損爲7800萬加元。
截至2024年3月31日，現金總額爲2.09億加元。
由領先的生物製藥機構投資者組成的銀團牽頭，完成了1.5億美元的超額認購。
Q4 2024 Financial Highlights...
20...
登入免費觀看全文
登入/註冊